Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized open-label study of Beovu (brolucizumab) in neovascular age-related macular degeneration
2019-004767-53Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2020
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of brolucizumab in exudative macular degeneration (2 arms), sponsored by Novartis. Primary endpoint: Mean change in BCVA from baseline to mean of visits at week 40 to week 52. Started Nov 2020; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-004767-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004767-53.